Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates BioSpace
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates FinancialContent
Endometriosis is a chronic gynecological disease affecting approximately 10% of women of reproductive age and up to 40% of women with infertility, with a significant impact on quality of life …
Transcriptome-based drug repurposing can accelerate therapeutic discovery, but is limited by fragmented resources, inconsistent quality control, and reliance on single perturbation databases. We developed CDRPipe ( C omputational D rug …
Infertility represents a significant global health burden, necessitating advanced therapeutic interventions. While Assisted Reproductive Technologies have revolutionized fertility treatment, they remain constrained by limited efficacy, off-target toxicity, and procedural complexity. …
Endometriosis is a chronic inflammatory disease characterised by ectopic endometrial tissue, progressive fibrosis and chronic pain, with a pathogenesis that goes beyond oestrogen dependence. The central question this review seeks …
Endometriosis is a debilitating chronic inflammatory disorder driven by extensive molecular reprogramming. Despite significant bench research into its pathogenesis, translating these molecular discoveries into clinical practices that improve patient outcomes …
Lactate is increasingly recognized not only as a metabolic end product of glycolysis but also as a signaling metabolite that links metabolic reprogramming to epigenetic and transcriptional regulation through protein …
Faeth Therapeutics Rebrands, Relocates and Overhauls Leadership The Globe and Mail
Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline The Manila Times